NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
Clinical Trials
9 trialsNCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT05541341 2025-06-06
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Novartis
Recruiting
NCT02435849 2024-02-13
ELIANA
Novartis
Phase 2 Completed
NCT04225676 2023-01-30
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 2 Terminated
NCT05349201 2022-07-01
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
Novartis
Completed
NCT03123939 2021-07-21
Phase III B in Acute Lymphoblastic Leukemia
Novartis
Phase 3 Completed
NCT02228096 2020-11-23
ENSIGN
Novartis
Phase 2 Completed
NCT03628053 2020-07-09
OBERON
Novartis
Phase 3 Withdrawn